All Patrick Johnson Articles
-
73Latest Myopia NewsSydnexis Receives European Commission Approval of SYD-101
June 6, 2025 DEL MAR, Calif. — Sydnexis‘ proprietary low-dose atropine formulation, SYD-101, has received marketing authorization from the European Commission (EC)....
-
1.4KLatest Myopia News
Sydnexis Receives Positive Opinion in Europe for SYD-101
April 2, 2025 DEL MAR, Calif. — Sydnexis has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human...
-
1.0KLatest Myopia NewsFDA Accepts New Drug Application for Sydnexis’ SYD-101
March 11, 2025 DEL MAR, Calif. — The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for...
-
1.1KLatest Myopia NewsSydnexis Names Perry J. Sternberg CEO
July 16, 2024 DEL MAR, Calif. — Sydnexis has officially named a new Chief Executive Officer and member of the Board of...
-
1.7KLatest Myopia NewsSydnexis Names Nick Ruth as Chief Commercial Officer
SAN DIEGO — Sydnexis Inc., a clinical stage biopharmaceutical company focused on the treatment of progressive myopia in children and minimizing the...
-
2.2KClinicalSafe and Effective Low-Dose Atropine Can Be Stable and Comfortable Too
sponsored content August 15, 2023 Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence...